| Dr Anh Trong Nguyen, MD | |
|
111 N Sepulveda Blvd, Suite 210, Manhattan Beach, CA 90266-6861 | |
| (310) 379-2134 | |
| Not Available |
| Full Name | Dr Anh Trong Nguyen |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 16 Years |
| Location | 111 N Sepulveda Blvd, Manhattan Beach, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467642926 | NPI | - | NPPES |
| 253802 | Other | NY | MEDICAL LICENSE |
| A111276 | Other | CA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A111276 (California) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Regents Of The University Of California | 1355248584 | 1177 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | The Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235107566 PECOS PAC ID: 1355248584 Enrollment ID: O20031223000439 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | West Hills Emergency Medical Associates, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275761249 PECOS PAC ID: 6800949553 Enrollment ID: O20090729000217 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | Regents University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710287297 PECOS PAC ID: 4082895677 Enrollment ID: O20110302000795 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891110888 PECOS PAC ID: 5294958815 Enrollment ID: O20140528001538 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anh Trong Nguyen, MD Po Box 5011, Sherman Oaks, CA 91413 Ph: () - | Dr Anh Trong Nguyen, MD 111 N Sepulveda Blvd, Suite 210, Manhattan Beach, CA 90266-6861 Ph: (310) 379-2134 |
News Archive
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact.
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago
Gregor Mciver, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 836 14th St, Manhattan Beach, CA 90266 Phone: 310-346-9422 | |
Peter James Bloomfield, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 229 16th St, Manhattan Beach, CA 90266 Phone: 310-218-7002 | |
Dr. Albert Tuong-quang Nguyen, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1467 6th St, Manhattan Beach, CA 90266 Phone: 909-528-7026 | |
Sandra Isnasious, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3215 N Sepulveda Blvd, Manhattan Beach, CA 90266 Phone: 424-295-0540 | |
David Sung Kwon, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 N Sepulveda Blvd, #210, Manhattan Beach, CA 90266 Phone: 310-379-2134 | |
Jose L Cervantes, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 N Sepulveda Blvd, #543, Manhattan Beach, CA 90266 Phone: 424-217-3227 | |
Andrea W Wu, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 N Sepulveda Blvd, Suite 210, Manhattan Beach, CA 90266 Phone: 310-379-2134 |